La cadena de opciones muestra datos clave de las opciones de acciones de IO Biotech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para IO Biotech..

IO Biotech (NASDAQ:IOBT) Bolsa, Cadena de Opciones

IO BIOTECH INC

IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.

Five,Below,Now,Open,-,Closeup,Of,Sign,On,Building

AGMH

AKBA

BHIL

DEVS

EFXT

FIVE

IOBT

MAZE

MHUA

OPTN

RVSB

VRPX

ZCAR

Las acciones de Five Below se disparan tras superar expectativas. Conoce otros grandes movimientos bursátiles en el premercado de EE.UU.

Las acciones de Five Below (FIVE) suben un 12%; Aquí están 20 acciones que se mueven en premercado

IO Biotech Inc

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 305.46% on an annualized basis producing an average annual return of 320.73%. Currently, Quest Diagnostics has a market capitalization of $19.47 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,318,296.30 today based on a price of $174.39 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747437313_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) has outperformed the market over the past 5 years by 10.77% on an annualized basis producing an average annual return of 26.04%. Currently, Wells Fargo has a market capitalization of $244.55 billion. 
Buying $1000 In WFC: If an investor had bought $1000 of WFC stock 5 years ago, it would be worth $2,998.03 today based on a price of $75.15 for WFC at the time of writing.
<h3>Wells Fargo's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747436412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Wells Fargo 5 Years Ago Would Be Worth Today

If it feels harder to build wealth these days, you're not imagining it—and the late Charlie Munger agreed.
In a <a href="https://www.cnbc.com/2023/11/30/full-transcript-from-cnbcs-charlie-munger-a-life-of-wit-and-wisdom-.html">2023 CNBC interview with Becky Quick</a>, Munger—who was 99 at the time—was asked a simple but loaded question:
"So you think it's harder to make money now?"
Munger didn't hesitate. "Well, that's a very interesting question. And it's a very important question. And of course it's harder. It's so much harder you can't believe it."
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
For someone who spent nearly a century analyzing markets, that blunt answer was striking. And it <a href="https://www.benzinga.com/personal-finance/25/01/43270288/its-almost-been-too-easy-charlie-munger-predicted-tough-times-ahead-for-investors-with-everything-doing-poorly-and-taxes-going-up">wasn't just a complaint—it was a history lesson</a>.
Munger explained that the investing playbook that made Warren Buffett rich, taught by legendary investor Ben Graham, doesn't work like it used to. Graham's strategy—buying undervalued companies with strong asset backing—was revolutionary during the Great Depression. He wasn't chasing unicorn startups or IPO hype. He just found "a few good things" and stuck with them for a few years.
"He just floated around from the best available stuff among companies good and bad. That was his system," Munger recalled. "Well, after he became so famous, partly with the help of Warren Buffett… everybody tried to do the same thing."
And that's the problem. The moment everyone flooded the market trying to be the next Ben Graham, the opportunities dried up. "The low-hanging fruit that Ben Graham had a lot of… has gone away," Munger said.
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
It's not just the investing world that's more competitive—every part of the wealth-building journey feels heavier now. Sure, Buffett has famously said that even today's <a href="https://www.benzinga.com/personal-finance/24/12/42558080/warren-buffett-says-the-poorest-2-of-earners-live-better-than-john-d-rockefeller-richest-man-in-the-world-people-have-more-money-now">bottom 2% are richer than Rockefeller</a> in many ways. And Munger himself has urged people <a href="https://www.benzinga.com/personal-finance/24/12/42416245/charlie-munger-found-it-weird-how-life-was-pretty-brutal-and-short-but-now-things-are-600-better-and-yet-people-are-less-happy">not to complain too much about modern life</a>. But that doesn't mean people feel rich. Not with inflation hammering everyday costs, home prices surging, and savings rates lagging behind asset inflation.
Yes, technology has opened doors. But it's also raised the bar. Everyone has access to information, apps, and trading tools. But that access <a href="https://www.benzinga.com/personal-finance/25/02/43718032/warren-buffett-was-asked-how-a-regular-person-gets-rich-he-detailed-exactly-how-hed-make-30-billion-starting-over-with-only-10000">hasn't made it easier to get rich</a>—it's just made the race more crowded.
What Munger was saying—in his signature blunt manner—is that the easy wins are gone. If you want to <a href="https://www.benzinga.com/money/are-you-rich">build wealth today</a>, you'll need more than just hustle. You'll need patience, strategy, and a willingness to climb higher for what used to be waiting on the ground.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
</ul>
Image: Shutterstock

Personal Finance

Charlie Munger Said 'It's So Much Harder To Make Money Today, You Can't Believe It' — The 'Low-Hanging Fruit' That Made People Rich Is Gone

Chardan Capital analyst Geulah Livshits maintains Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) with a Buy and lowers the price target from $7 to $6.

Price Target

Analyst Ratings

IPSC

Chardan Capital Maintains Buy on Century Therapeutics, Lowers Price Target to $6

Canaccord Genuity analyst Joseph Vafi maintains IREN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) with a Buy and maintains $23 price target.

IREN

Canaccord Genuity Maintains Buy on IREN, Maintains $23 Price Target

Before Mark Cuban became a billionaire, a TV fixture, and a guy who <a href="https://www.benzinga.com/personal-finance/25/04/44839817/billionaire-mark-cuban-says-pharma-is-the-easiest-business-ive-ever-disrupted-in-a-500-billion-industry-1-is-a-whole-lot-of-money">casually disrupts Big Pharma</a> for fun, he was just another confident tech founder trying to make it in the ‘80s. He had a million-dollar company, a little swagger, and—at least for one night in Las Vegas—a front-row seat to what happens when <a href="https://www.benzinga.com/personal-finance/25/05/45332405/bill-gates-predicts-3-day-workweeks-says-its-probably-ok-if-machines-can-make-the-food-and-stuff-because-theres-more-to-life-than-work">Bill Gates walks into a bar</a>.
It all came up <a href="https://youtu.be/L_8wm30tLyc?si=KP1btYratigTdZB8">during a 2022 episode of the "Full Send Podcast"</a>, after the hosts asked Cuban about competition and missed opportunities. That's when he lit up with:
"I'll tell you a story. I'll tell you a story about in Vegas back in the day about Bill Gates."
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
This wasn't just any Vegas story—it was COMDEX, one of the biggest tech trade shows in the world at the time. According to Cuban, the crowd was massive. "125,000 people," he said. "I started my company, I was like 26, 27… and I just thought I was a badass."
He was feeling good, hanging with a group of women, ordering shots, and <a href="https://www.benzinga.com/personal-finance/25/01/43190697/mark-cubans-black-amex-card-got-declined-buying-a-140000-bottle-of-champagne-to-celebrate-teams-nba-win-can-i-please-spend-some-money">assuming the night was going his way</a>.
"This was right when <a href="https://learn.microsoft.com/en-us/shows/history/history-of-microsoft-1986">Microsoft had gone public</a>," he said. "So one day, no one knows who Bill Gates is. The next day, he's the king of tech."
That's when the girls told him they needed to run to the bathroom—and never returned.
"I'm like, what the f&#x2A;&#x2A;&#x2A;?" Cuban said, still laughing about it decades later.
His buddy leaned over and broke the news: "Yo, do you know who Bill Gates is?"
Trending: The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a>
Turns out Gates had just hit a net worth of around $350 million. Cuban? "I was maybe worth a million dollars." Which made him… invisible.
"Bill Gates took my girls!" he admitted, laughing. But the sting was real.
The host cut in: "Did that fire you up? That should've motivated you, right?"
"It did motivate me," Cuban shot back. "Right? To find—to go on to the next…"
Years later, Cuban finally got a chance to one-up the tech legend. After selling Broadcast.com, he was invited to speak at a conference. The organizers mentioned Gates would be speaking first.
"I'm like, the only reason I'm doing this is because Bill Gates is talking right before me," he said.
See Also: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
So when it was his turn, he walked out on stage and delivered the zinger he'd probably been waiting years to say:
"I'm excited to tell you I sold my company… and finally, after all these years, Bill Gates is my opening act."
Cuban says Gates "got so pissed." And the kicker?
"I've never talked to him since," Cuban said. "Not to this day."
Not out of spite. "Not that I've had any reason to talk to him," he added. But that night in Vegas? Still a core memory.
He may have lost the girls, but Cuban got the punchline. And maybe a little satisfaction knowing that even tech royalty doesn't always get the last word.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Mark Cuban Says 'Back In The Day' Bill Gates Stole 'His Girls' In Las Vegas — He Was Worth $1 Million, But Gates Was The Mega Rich 'King of Tech'

Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) has outperformed the market over the past 10 years by 2.4% on an annualized basis producing an average annual return of 13.17%. Currently, Xylem has a market capitalization of $31.16 billion. 
Buying $1000 In XYL: If an investor had bought $1000 of XYL stock 10 years ago, it would be worth $3,478.13 today based on a price of $128.03 for XYL at the time of writing.
<h3>Xylem's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747434613_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Xylem 10 Years Ago Would Be Worth Today

Wells Fargo analyst Tiago Fauth downgrades Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) from Overweight to Equal-Weight and announces $4 price target.

Downgrades

INZY

Wells Fargo Downgrades Inozyme Pharma to Equal-Weight, Announces $4 Price Target

UBS analyst Christopher Schoell maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Buy and raises the price target from $230 to $275.

TTWO

UBS Maintains Buy on Take-Two Interactive, Raises Price Target to $275

UBS analyst Leonardo Olmos maintains Millicom Intl Cellular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) with a Buy and raises the price target from $31.5 to $39.5.

TIGO

UBS Maintains Buy on Millicom Intl Cellular, Raises Price Target to $39.5

UBS analyst Karl Keirstead maintains Informatica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INFA#NYSE">INFA</a>) with a Neutral and raises the price target from $20 to $21.

INFA

UBS Maintains Neutral on Informatica, Raises Price Target to $21

UBS analyst Taylor McGinnis maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Neutral and raises the price target from $655 to $720.

INTU

UBS Maintains Neutral on Intuit, Raises Price Target to $720

AerCap Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AER#NYSE">AER</a>) has outperformed the market over the past 5 years by 16.97% on an annualized basis producing an average annual return of 32.24%. Currently, AerCap Holdings has a market capitalization of $20.50 billion. 
Buying $1000 In AER: If an investor had bought $1000 of AER stock 5 years ago, it would be worth $3,869.61 today based on a price of $113.07 for AER at the time of writing.
<h3>AerCap Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747433712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Freight Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>) reported quarterly losses of $(0.73) per share. This is a 93.22 percent increase over losses of $(10.76) per share from the same period last year. The company reported $4.10 million in sales this quarter. This is a 4.36 percent decrease over sales of $4.29 million the same period last year.

Earnings

FRGT

Freight Technologies Q1 EPS $(0.73) Up From $(10.76) YoY, Sales $4.10M Down From $4.29M YoY

SolarMax Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) reported quarterly losses of $(0.03) per share. This is a 93.48 percent increase over losses of $(0.46) per share from the same period last year. The company reported $6.93 million in sales this quarter. This is a 20.18 percent increase over sales of $5.76 million the same period last year.

SMXT

SolarMax Technology Q1 EPS $(0.03) Up From $(0.46) YoY, Sales $6.93M Up From $5.76M YoY

CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.61) by 13.11 percent. This is a 2.82 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $6.24 million which beat the analyst consensus estimate of $6.10 million by 2.30 percent. This is a 83.04 percent increase over sales of $3.41 million the same period last year.

Earnings Beats

Earnings Misses

CASI

CASI Pharmaceuticals Q1 EPS $(0.69) Misses $(0.61) Estimate, Sales $6.24M Beat $6.10M Estimate

In the preceding three months, 10 analysts have released ratings for Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $49.9, with a high estimate of $59.00 and a low estimate of $44.00. Observing a downward trend, the current average is 5.67% lower than the prior average price target of $52.90. 
<img src="https://www.benzinga.com/files/images/story/2025/1747432875_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Schlumberger. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Derek Podhaizer</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$46.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Schlumberger. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Schlumberger compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Schlumberger's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Schlumberger's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Schlumberger analyst ratings.</a>
<h2>All You Need to Know About Schlumberger</h2>
SLB is the world's premier oilfield-services company as measured by market share. While the industry is mostly fragmented, SLB holds the first or second competitive position in many of the differentiated oligopolies it operates in. Also known as Schlumberger, the company was founded in 1926 by two brothers bearing the same last name. Today it's most known as a global industry leader in innovation, while it focuses its strategy on its three growth engines: its core, digital, and new energy businesses. Over three fourths of its revenue base is tied to international markets, while the company boasts roughly $3 billion in digital-related revenue.
<h3>Schlumberger: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Decline in Revenue: Over the 3M period, Schlumberger faced challenges, resulting in a decline of approximately -2.49% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.39%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Schlumberger's ROE stands out, surpassing industry averages. With an impressive ROE of 3.92%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Schlumberger's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Schlumberger's debt-to-equity ratio surpasses industry norms, standing at 0.72. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Schlumberger: Insights From 10 Financial Analysts

MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) has been analyzed by 27 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">12</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">9</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated MongoDB and provided 12-month price targets. The average target is $280.67, accompanied by a high estimate of $350.00 and a low estimate of $160.00. A 20.77% drop is evident in the current average compared to the previous average price target of $354.26. 
<img src="https://www.benzinga.com/files/images/story/2025/1747432863_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of MongoDB among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$252.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$160.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$190.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$330.00</td>
<td>$430.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$315.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$335.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$340.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$300.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$330.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$320.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Bradley Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$286.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$415.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$320.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$305.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$350.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MongoDB. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MongoDB compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for MongoDB's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MongoDB's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MongoDB analyst ratings.</a>
<h2>Get to Know MongoDB Better</h2>
Founded in 2007, MongoDB is a vendor of a document-oriented database that accelerates development processes of new applications. Enterprise customers can choose between the fully managed offering, MongoDB Atlas, or the self-managed version, MongoDB Enterprise Advanced. MongoDB is a popular tool among developers, and its free Community Server has recorded over 500 million downloads since 2009.
<h3>MongoDB's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, MongoDB showcased positive performance, achieving a revenue growth rate of 19.74% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: MongoDB's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.89%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): MongoDB's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.74%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): MongoDB's ROA excels beyond industry benchmarks, reaching 0.48%. This signifies efficient management of assets and strong financial health.
Debt Management: MongoDB's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into MongoDB Stock: Analyst Perspectives (27 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $143.5, a high estimate of $179.00, and a low estimate of $96.00. This current average represents a 0.26% decrease from the previous average price target of $143.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1747432854_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of 3M among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$164.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Andrew Kaplowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$142.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to 3M. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of 3M compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of 3M's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of 3M's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on 3M analyst ratings.</a>
<h2>Discovering 3M: A Closer Look</h2>
3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.
<h3>3M: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, 3M faced challenges, resulting in a decline of approximately -1.03% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 18.74%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): 3M's ROE excels beyond industry benchmarks, reaching 26.87%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): 3M's ROA excels beyond industry benchmarks, reaching 2.8%. This signifies efficient management of assets and strong financial health.
Debt Management: 3M's debt-to-equity ratio is below the industry average at 3.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About 3M Stock

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Krystal Biotech, presenting an average target of $218.17, a high estimate of $245.00, and a low estimate of $155.00. Witnessing a positive shift, the current average has risen by 0.49% from the previous average price target of $217.10.
<img src="https://www.benzinga.com/files/images/story/2025/1747432843_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Krystal Biotech among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$155.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$189.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$219.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$240.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Roger Song</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$245.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$206.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$218.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$221.00</td>
<td>$221.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Krystal Biotech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Krystal Biotech compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Krystal Biotech's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Krystal Biotech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KRYS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Krystal Biotech analyst ratings.</a>
<h2>Get to Know Krystal Biotech Better</h2>
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
<h3>Krystal Biotech's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Krystal Biotech showcased positive performance, achieving a revenue growth rate of 94.88% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Krystal Biotech's net margin excels beyond industry benchmarks, reaching 40.52%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.7%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Krystal Biotech's ROA excels beyond industry benchmarks, reaching 3.35%. This signifies efficient management of assets and strong financial health.
Debt Management: Krystal Biotech's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRYS

The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts

Health Care

Press Releases

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

IO Biotech Reports 2024 Business Highlights

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

General

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Comments

IO Biotech

IO Biotech (IOBT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL